Literature DB >> 35194707

Predicting adverse cardiac events in sarcoidosis: deep learning from automated characterization of regional myocardial remodeling.

Chenying Lu1,2, Yi Grace Wang3, Fahim Zaman4, Xiaodong Wu4, Mehul Adhaduk5, Amanda Chang5, Jiansong Ji2, Tiemin Wei2, Promporn Suksaranjit5, Georgios Christodoulidis5, Ernest Scalzetti1, Yuchi Han6, David Feiglin1, Kan Liu7,8.   

Abstract

Recognizing early cardiac sarcoidosis (CS) imaging phenotypes can help identify opportunities for effective treatment before irreversible myocardial pathology occurs. We aimed to characterize regional CS myocardial remodeling features correlating with future adverse cardiac events by coupling automated image processing and data analysis on cardiac magnetic resonance (CMR) imaging datasets. A deep convolutional neural network (DCNN) was used to process a CMR database of a 10-year cohort of 117 consecutive biopsy-proven sarcoidosis patients. The maximum relevance - minimum redundancy method was used to select the best subset of all the features-24 (from manual processing) and 232 (from automated processing) left ventricular (LV) structural/functional features. Three machine learning (ML) algorithms, logistic regression (LogR), support vector machine (SVM) and multi-layer neural networks (MLP), were used to build classifiers to categorize endpoints. Over a median follow-up of 41.8 (inter-quartile range 20.4-60.5) months, 35 sarcoidosis patients experienced a total of 43 cardiac events. After manual processing, LV ejection fraction (LVEF), late gadolinium enhancement, abnormal segmental wall motion, LV mass (LVM), LVMI index (LVMI), septal wall thickness, lateral wall thickness, relative wall thickness, and wall thickness of 9 (out of 17) individual LV segments were significantly different between patients with and without endpoints. After automated processing, LVEF, end-diastolic volume, end-systolic volume, LV mass and wall thickness of 92 (out of 216) individual LV segments were significantly different between patients with and without endpoints. To achieve the best predictive performance, ML algorithms selected lateral wall thickness, abnormal segmental wall motion, septal wall thickness, and increased wall thickness of 3 individual segments after manual image processing, and selected end-diastolic volume and 7 individual segments after automated image processing. LogR, SVM and MLP based on automated image processing consistently showed better predictive accuracies than those based on manual image processing. Automated image processing with a DCNN improves data resolution and regional CS myocardial remodeling pattern recognition, suggesting that a framework coupling automated image processing with data analysis can help clinical risk stratification.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Adverse cardiac events; Automated image processing; Cardiac sarcoidosis; Deep learning; Regional myocardial remodeling

Year:  2022        PMID: 35194707     DOI: 10.1007/s10554-022-02564-5

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  37 in total

Review 1.  Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment.

Authors:  George Youssef; Rob S B Beanlands; David H Birnie; Pablo B Nery
Journal:  Heart       Date:  2011-12       Impact factor: 5.994

2.  Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation.

Authors:  Toshiyuki Nagai; Shun Kohsaka; Shigeo Okuda; Toshihisa Anzai; Koichiro Asano; Keiichi Fukuda
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

3.  Cardiac Sarcoidosis: The Challenge of Radiologic-Pathologic Correlation—Erratum.

Authors:  Jean Jeudy; Allen P Burke; Charles S White; Gerdien B G Kramer; Aletta Ann Frazier
Journal:  Radiographics       Date:  2015 Jul-Aug       Impact factor: 5.333

4.  Prognostic Value of CMR-Verified Myocardial Scarring in Cardiac Sarcoidosis: What to Learn From a Systematic Review and Meta-Analysis?

Authors:  Albert de Roos; Annette van den Berg-Huysmans; Jan W Schoones
Journal:  JACC Cardiovasc Imaging       Date:  2017-04

5.  T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis.

Authors:  Valentina O Puntmann; Alexander Isted; Rocio Hinojar; Lucy Foote; Gerald Carr-White; Eike Nagel
Journal:  Radiology       Date:  2017-04-27       Impact factor: 11.105

6.  Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis.

Authors:  Vasileios Kouranos; George E Tzelepis; Aggeliki Rapti; Sofia Mavrogeni; Konstantina Aggeli; Marousa Douskou; Sanjay Prasad; Nikolaos Koulouris; Petros Sfikakis; Athol Wells; Elias Gialafos
Journal:  JACC Cardiovasc Imaging       Date:  2017-03-15

Review 7.  Pathophysiology and clinical management of cardiac sarcoidosis.

Authors:  Nabeel Hamzeh; David A Steckman; William H Sauer; Marc A Judson
Journal:  Nat Rev Cardiol       Date:  2015-02-24       Impact factor: 32.419

8.  Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis.

Authors:  Jan-Peter Smedema; Gabriel Snoep; Marinus P G van Kroonenburgh; Robert-Jan van Geuns; Willem R M Dassen; Anton P M Gorgels; Harry J G M Crijns
Journal:  J Am Coll Cardiol       Date:  2005-04-25       Impact factor: 24.094

9.  Detection of myocardial damage in patients with sarcoidosis.

Authors:  Manesh R Patel; Peter J Cawley; John F Heitner; Igor Klem; Michele A Parker; Wael A Jaroudi; Trip J Meine; James B White; Michael D Elliott; Han W Kim; Robert M Judd; Raymond J Kim
Journal:  Circulation       Date:  2009-11-02       Impact factor: 29.690

Review 10.  Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis.

Authors:  G Cameron Coleman; Peter W Shaw; Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer; Amit R Patel; Michael Salerno
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.